Valuation: VERE THER

Market Cap 994M 870M 802M 741M 1.41B 94.82B 1.43B 9.58B 3.76B 46.71B 3.73B 3.65B 161B P/E 2023
-4.47x
P/E 2024 -2.4x
Enterprise Value 540M 472M 436M 402M 763M 51.49B 776M 5.2B 2.04B 25.36B 2.03B 1.98B 87.2B EV / Sales 2023
46,430,598x
EV / Sales 2024 717,743x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 year 10.9
Extreme 10.9
11.25
3 years 2.86
Extreme 2.8647
21.04
5 years 2.86
Extreme 2.8647
78
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 25/07/2025
Date Insider Type Main position Quantity % Market Cap.
25/07/25Issuer sale

Director

178,339 0.2106%
25/07/25Tender

Chief Financial Officer

606,905 0.7168%
25/07/25Tender

Chief Administrative Officer

534,066 0.6308%

Financials

2023 2024
Net sales 11.76 10.28 9.49 8.76 16.62 1.12K 16.9 113.35 44.51 552.44 44.15 43.19 1.9K 32.33 28.28 26.09 24.09 45.71 3.08K 46.48 311.68 122.4 1.52K 121.4 118.76 5.22K
Net income -200M -175M -161M -149M -283M -19.08B -288M -1.93B -757M -9.4B -751M -735M -32.32B -199M -174M -160M -148M -281M -18.95B -286M -1.92B -752M -9.34B -746M -730M -32.1B
Net Debt -549M -480M -443M -409M -776M -52.36B -789M -5.29B -2.08B -25.8B -2.06B -2.02B -88.68B -454M -397M -367M -339M -642M -43.33B -653M -4.38B -1.72B -21.34B -1.71B -1.67B -73.38B
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. VERV Stock